InsidersTradesSigma
Track the West Pharmaceutical Services INC share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, West Pharmaceutical Services INC has logged 148 public disclosures. Market capitalisation: €25.4bn. The latest transaction was filed on 14 May 2026 (Levée d'options). Among the most active insiders: Winters Chad. The full history is accessible without an account.
148
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€20m
13 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate West Pharmaceutical Services INC Strong Buy (bullish), based on 15 analysts. Average price target: US$382.00.
47Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 12,893 of 29,062 companies
54.9
score / 100
Value35
Quality74
FCF yld2.0%
Earn yld2.1%
EV/EBITDA31.1x
ROE19%
Gross mgn36%
Net mgn16%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 14 May 2026
Declarations148 total
295.995 sharesCommon StockSEC:0000105770-26-000075:0
2,817 shares@ US$83.470.0009% mcap6.4% of flowCommon StockSEC:0000105770-26-000054:0
2,817 shares@ US$305.20180.0032% mcap23.2% of flowCommon StockSEC:0000105770-26-000054:1
896 shares@ US$173.220.0006% mcap12.6% of flowCommon StockSEC:0000105770-26-000053:0
896 shares@ US$300.66880.0010% mcap21.9% of flowCommon StockSEC:0000105770-26-000053:1
1,071 shares0Common StockSEC:0001127602-25-013688:0
1,071 shares0Common StockSEC:0001127602-25-013705:0
1,071 shares0Common StockSEC:0001127602-25-013693:0
1,071 shares0Common StockSEC:0001127602-25-013724:0
1,071 shares0Common StockSEC:0001127602-25-013718:0
1,071 shares0Common StockSEC:0001127602-25-013709:0
1,071 shares0Common StockSEC:0001127602-25-013700:0
1,071 shares0Common StockSEC:0001127602-25-013696:0
1,071 shares0Common StockSEC:0001127602-25-013716:0
1,071 shares0Common StockSEC:0001127602-25-013704:0
1,071 shares0Common StockSEC:0001127602-25-013728:0
2,460.991 shares@ US$211.001.6% of flowCommon StockSEC:0001127602-25-006115:0
246.162 shares@ US$211.0020.3% of flowCommon StockSEC:0001127602-25-006120:0
246.162 shares@ US$211.009.8% of flowCommon StockSEC:0001127602-25-006123:0
82.054 shares@ US$211.002.4% of flowCommon StockSEC:0001127602-25-006118:0
246.162 shares@ US$211.002.2% of flowCommon StockSEC:0001127602-25-006119:0
779.353 shares@ US$211.001.0% of flowCommon StockSEC:0001127602-25-006135:0
65.706 shares@ US$211.001.8% of flowCommon StockSEC:0001127602-25-006117:0
247 sharesCommon StockSEC:0001127602-25-001388:0
424 sharesCommon StockSEC:0001127602-24-029751:0
25 of 148 declarations
关于 West Pharmaceutical Services INC
West Pharmaceutical Services, Inc. (NYSE: WST) 是美国医疗保健供应链中的领先企业。公司总部位于宾夕法尼亚州埃克斯顿，为注射药物的储存、包装和输送开发并提供高价值解决方案。其客户群主要包括制药公司、生物技术公司和药物开发商，在无菌注射和复杂治疗应用领域拥有特别强大的地位。West 成立于 1923 年，凭借在材料科学、精密工程和法规遵从方面的专业知识，数十年来已成为注射药物行业的重要合作伙伴。([investor.westpharma.com](https://investor.westpharma.com/?utm_source=openai)) West 通过两个主要部门运营。第一个部门是专有产品（Proprietary Products），包括公司自有品牌的注射药物组件和系统：高价值组件、封闭解决方案、输送设备和标准产品。第二个部门是合同制造产品（Contract-Manufactured Products），涵盖合同制造活动，包括与自注射设备和其他注射输送系统相关的工作。这种结构赋予 West 混合型企业形象：它既是基本组件的制造商，也是制药客户的开发/工业合作伙伴。([investor.westpharma.com](https://investor.westpharma.com/news-releases/news-release-details/west-reports-fourth-quarter-and-full-year-2025-results?utm_source=openai)) 从竞争角度来看，West 占据着一个利基但具有战略重要性的地位。公司本身不销售药物；相反，它提供关键的投入，以保护产品完整性，支持精确剂量，并实现安全给药。这使得它深度嵌入制药价值链中，并且通常难以替代，特别是对于高规格注射产品。近期产品重点包括 Westar®、Envision®、NovaPure®、Daikyo PLASCAP® 和 SmartDose®，这显示了其技术平台的广度及其对更高价值产品的重视。([investor.westpharma.com](https://investor.westpharma.com/news-releases/news-release-details/west-reports-fourth-quarter-and-full-year-2025-results?utm_source=openai)) 在地理上，West 拥有全球业务足迹，运营中心位于美国，并在多个地区拥有制造/商业能力。近期披露强调了其都柏林工厂的扩建，以支持大批量注射疗法，包括糖尿病和肥胖症，从而增强了其在现代医疗保健领域对大型、长期增长市场的敞口。([investor.westpharma.com](https://investor.westpharma.com/news-releases/news-release-details/west-expands-dublin-facility-support-high-volume-injectable?utm_source=openai)) 近期发展具有建设性。2025 年，West 取得了稳健的业绩并上调了指引，2026 年第一季度，公司报告了强劲的收入和盈利增长，并再次上调了全年预期。公司还宣布计划将 SmartDose® 3.5mL 剥离给 AbbVie，同时持续进行工业投资和股票回购。因此，对于法语投资者而言，West 作为一家在美国纽约证券交易所上市的高质量医疗保健和制药公司脱颖而出，对注射输送系统、生物制剂和长期制药外包趋势具有吸引力的敞口。([investor.westpharma.com](https://investor.westpharma.com/news-releases/news-release-details/west-reports-fourth-quarter-and-full-year-2025-results?utm_source=openai))
